If you have spent years being told your joints are ‘just flexible’, that your fatigue is anxiety, or that your pain is disproportionate to what the scans show, there is a reasonable chance hypermobility has never been seriously considered. That is not a fringe experience. For many people with hypermobility spectrum disorder (HSD) or hypermobile Ehlers-Danlos syndrome (hEDS), the path to a meaningful diagnosis runs through a decade of appointments, misdiagnoses and, frequently, being made to feel like the problem is psychological. The hypermobility chronic pain NHS UK picture is improving, slowly, but patients still need to understand what they are dealing with and what they can reasonably expect.
What hypermobility spectrum disorder actually is
Hypermobility refers to joints that move beyond the normal range. In children, some degree of flexibility is common and usually harmless. The clinical picture changes significantly when hypermobility comes with chronic pain, fatigue, frequent joint injuries, proprioception problems, and a range of systemic symptoms that do not fit neatly into any single specialty.
The 2017 international classification separated hEDS from HSD to reflect that these are related but distinct conditions. hEDS is diagnosed using specific clinical criteria around joint hypermobility, skin features and family history. HSD covers patients who have symptomatic hypermobility without meeting the full hEDS criteria. Crucially, both conditions cause real, significant disability. The distinction matters for research purposes but should not imply that HSD is a lesser diagnosis deserving less support.
Connective tissue is present throughout the body, which is why the symptom list is so wide. Beyond joint pain and instability, many patients deal with gastrointestinal problems, bladder dysfunction, chronic fatigue, and dysautonomia. That last one, particularly postural tachycardia syndrome (PoTS), is underrecognised and often the symptom that sends patients spiralling through cardiology, neurology and psychiatry before anyone joins the dots.
Why dysautonomia keeps getting missed
Dysautonomia is a dysfunction of the autonomic nervous system, the part that regulates heart rate, blood pressure, digestion and temperature control. In hypermobile patients, PoTS is the most common form. Standing up causes heart rate to spike by 30 beats per minute or more within ten minutes, producing dizziness, brain fog, nausea and sometimes fainting. The NHS describes PoTS as often taking years to diagnose partly because symptoms mimic anxiety, and partly because lying-down examinations will look completely normal.
I have spoken to patients who were discharged from cardiology with ‘no structural abnormality’ after a routine ECG, then spent another two years cycling back through their GP before anyone performed a simple active stand test. That test takes minutes. The delay does not reflect a lack of good clinicians; it reflects a system organised around organ-specific specialties that struggles with conditions that are inherently systemic.
How long does diagnosis actually take in the UK?
The Ehlers-Danlos Support UK charity has surveyed its members repeatedly and the results are consistent: average time from first seeking help to diagnosis with hEDS or HSD runs to around ten years. That figure has been cited in parliamentary discussions and has not shifted dramatically even as awareness has grown. Part of the delay is structural. There is no single NHS specialty that ‘owns’ hypermobility. Rheumatology, physiotherapy, genetics and pain medicine all have a claim, and which door a patient gets through first is largely down to chance and geography.
There is also a troubling pattern around gender. The majority of hEDS and HSD patients are women, and the symptoms, particularly fatigue and widespread pain, are historically more likely to be attributed to anxiety or depression in female patients. This is not unique to hypermobility; it is a documented pattern across several chronic conditions. But it compounds the diagnostic delay significantly.
The fatigue element is worth addressing directly. Many hypermobility patients meet criteria for what was previously called chronic fatigue syndrome. The body is working harder simply to stabilise joints, the autonomic dysfunction disrupts sleep, and pain is itself exhausting. If you are navigating that combination, the situation facing ME/CFS patients in the NHS in 2026 is closely relevant reading, because the service gaps overlap considerably.
What NICE guidance and NHS specialist pathways actually offer
NICE does not currently have a dedicated guideline specifically for hEDS or HSD. Management draws on guidance for related conditions: chronic pain (NG193, published 2021), PoTS, and physiotherapy for joint hypermobility. NG193 represents a genuine shift in how the NHS is supposed to approach chronic pain, moving away from purely biomedical models towards personalised care that includes psychological support alongside physical treatment. In practice, implementation is patchy. Pain clinics vary enormously in quality and waiting times.
For specialist input, NHS England has commissioned a small number of hypermobility clinics, mostly concentrated in London and a few other urban centres. The Hypermobility Unit at the Hospital of St John and St Elizabeth (now operating privately) and the NHS clinic at University College London Hospital are among the most referenced. Outside these centres, most patients are managed in general rheumatology or through physiotherapy alone, which is insufficient for the complexity most of them present with.
Physiotherapy is the cornerstone of physical management and the evidence supports it, but the emphasis has shifted. Passive stretching is actively counterproductive in hypermobility. Proprioception training, joint stabilisation and carefully progressed strength work are what the evidence points to. The parallel here is worth noting: the case for strength-based exercise in managing chronic musculoskeletal conditions is consistent across the research, much as it is when looking at strength training’s benefits for adults managing chronic conditions later in life.
Managing chronic pain when the system keeps you waiting
A realistic read of the current NHS landscape is that most hypermobile patients will not quickly access a specialist clinic. They will manage symptoms partly through physiotherapy, partly through their GP, and partly through their own research. That is not ideal, but it is the current reality.
A few things are worth knowing. Referral to a genetics clinic can be useful for formal hEDS classification, though waiting lists are long. PoTS, once suspected, can be tested simply with a GP-arranged lying and standing blood pressure and heart rate check. Many GPs will not have initiated this themselves, but they can arrange it once a patient raises it specifically.
Pacing strategies, borrowed from ME/CFS management, are genuinely helpful for fatigue. The instinct to push through pain on good days and crash on bad ones is understandable but makes the cycle worse. Activity management based on a sustainable baseline, then gradual increments, is the approach most specialist physiotherapists will take.
Medication for pain is limited in its usefulness. The 2021 NICE guidance on chronic primary pain explicitly moved away from recommending paracetamol, NSAIDs and opioids as the default response, which is significant given how many hypermobility patients have been handed these as a first-line response for years. Low-dose naltrexone and duloxetine are among the options discussed in specialist contexts, but neither is a quick fix and both should be managed with medical oversight.
Where patient advocacy makes a practical difference
Ehlers-Danlos Support UK runs helplines, condition guides and connects patients with healthcare professionals who have specific experience. Their resources are genuinely useful for preparing for appointments and understanding what to ask for. The Hypermobility Syndromes Association (HMSA) similarly provides practical support and has a directory of healthcare professionals with relevant experience.
Self-advocacy is not a phrase that should be needed in a functional health system. But for patients who have spent years being told nothing is wrong, having a clear vocabulary for what you are experiencing, the specific diagnostic criteria, the associated conditions to raise, the tests that are appropriate, makes appointments more productive. It should not be that way. It currently is.
Chronically complex conditions handled patchily by a stretched NHS tend to push patients towards self-directed solutions, and not all of those solutions are evidence-based. The supplement market is enthusiastic about hypermobility. Magnesium, vitamin C and collagen products are widely marketed to connective tissue disorder patients. Some have a plausible rationale; most lack robust trial evidence in this specific population. If you are thinking through supplementation, the evidence around magnesium deficiency and supplementation in the UK is a reasonable starting point for calibrating expectations.
The hypermobility chronic pain NHS UK picture is genuinely difficult right now. Awareness is higher than it was, specialist services exist but are limited, and the diagnostic journey remains far too long for too many people. That does not make it hopeless. Physiotherapy, pacing, accurate diagnosis of associated conditions like PoTS, and engagement with patient charities all make a real difference. The wait for systemic improvement continues, but there is more support available today than there was five years ago.
Frequently Asked Questions
How do I get referred for hypermobility assessment on the NHS?
Start with your GP and ask specifically for a referral to rheumatology or a hypermobility clinic if one is accessible in your area. Bringing a clear symptom timeline and mentioning the Beighton score criteria can help focus the conversation. NHS England has commissioned a small number of specialist hypermobility services, though access depends heavily on where you live.
What is the difference between hEDS and hypermobility spectrum disorder?
Both involve symptomatic joint hypermobility, but hEDS requires meeting specific clinical criteria set out in the 2017 international classification, including features like skin involvement and a positive family history. HSD is diagnosed when significant symptoms are present but the full hEDS criteria are not met. Both cause real disability and should be taken seriously by clinicians.
Can hypermobility cause fatigue as well as joint pain?
Yes, and this is frequently underestimated. The body uses significantly more muscular effort to stabilise hypermobile joints, autonomic dysfunction disrupts sleep quality, and chronic pain is itself draining. Many hypermobility patients meet diagnostic criteria for chronic fatigue conditions alongside their musculoskeletal symptoms.
What is PoTS and how is it connected to hypermobility?
Postural tachycardia syndrome (PoTS) is a form of dysautonomia where standing causes a rapid heart rate increase, producing dizziness, brain fog and sometimes fainting. It is significantly more common in people with hypermobile connective tissue disorders. A basic lying and standing heart rate test is usually the first diagnostic step and can be arranged through your GP.